Aclaris Therapeutics (ACRS) FCF Margin (2017 - 2026)
Aclaris Therapeutics (ACRS) posted quarterly FCF Margin of 912.27% for Q1 2026, down 1193.0% year-over-year from 83.47% in Q1 2025, and up 10.7% quarter-over-quarter from 1021.62% in Q4 2025.
Aclaris Therapeutics (ACRS) FCF Margin (2017 - 2026) Analysis & Trends
Aclaris Therapeutics' FCF Margin history runs 10 years deep, the most recent figure standing at 912.27% for Q1 2026.
- In Q1 2026, FCF Margin fell 1193.0% year-over-year to 912.27%; the TTM figure through Mar 2026 stood at 625.47% (down 55602.0% YoY), while the FY2025 annual figure was 603.42%, down 49554.0% from the prior year.
- FCF Margin for Q1 2026 stood at 912.27%, up from 1021.62% in the prior quarter.
- The five-year high for FCF Margin was 506.21% in Q3 2024, with the low at 1450.79% in Q1 2022.
- The 5-year median for FCF Margin is 563.53% (2025), against an average of 597.0%.
- The sharpest annual moves came in 2022 and 2025: FCF Margin surged 91049 bps in 2022, then tumbled 92459 bps in 2025.
- Aclaris Therapeutics' FCF Margin stood at 240.41% in 2022, then soared by 82 bps to 43.79% in 2023, then sank by 122 bps to 97.04% in 2024, then slumped by 953 bps to 1021.62% in 2025, then rose by 11 bps to 912.27% in 2026.
- Business Quant data shows ACRS's FCF Margin at 912.27% in Q1 2026, 1021.62% in Q4 2025, and 329.8% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn | -1,219.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,219.03% |
| Mar 31, 2026 | -912.27% |
| Dec 31, 2025 | -1,021.62% |
| Sep 30, 2025 | -329.80% |
| Jun 30, 2025 | -563.53% |
| Mar 31, 2025 | -900.34% |
| Dec 31, 2024 | -97.04% |
| Sep 30, 2024 | 506.21% |
| Jun 30, 2024 | -444.97% |
| Mar 31, 2024 | -873.64% |
| Dec 31, 2023 | -43.79% |
| Sep 30, 2023 | -264.37% |
| Jun 30, 2023 | -1,123.97% |
| Mar 31, 2023 | -1,044.07% |
| Dec 31, 2022 | -240.41% |
| Sep 30, 2022 | -41.89% |
| Jun 30, 2022 | -1,302.68% |
| Mar 31, 2022 | -1,450.79% |
| Dec 31, 2021 | -1,150.90% |
| Sep 30, 2021 | -642.68% |